Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.54 -6.6%	$2.48	$1.78 ▼ $10.14	$53.06M	0.7	264,156 shs	65,761 shs
AERI Aerie Pharmaceuticals	$15.25	$15.23	$4.81 ▼ $15.37	$753.61M	-0.06	974,748 shs	600 shs
ALGS Aligos Therapeutics	$8.36 -4.9%	$6.63	$3.76 ▼ $46.80	$51.08M	2.77	212,103 shs	60,315 shs
CLLS Cellectis	$1.59 -3.6%	$1.49	$1.10 ▼ $2.43	$88.37M	2.91	142,976 shs	17,240 shs
PASG Passage Bio	$0.40 +0.9%	$0.38	$0.26 ▼ $1.33	$24.92M	1.67	393,558 shs	2.95 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+7.09%	+14.05%	-2.51%	-20.70%	-65.04%
AERI Aerie Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ALGS Aligos Therapeutics	+1.50%	+10.57%	+20.41%	+115.44%	-31.03%
CLLS Cellectis	+1.54%	+4.10%	+17.02%	+14.58%	-15.38%
PASG Passage Bio	-9.86%	-13.77%	-17.10%	+9.66%	-51.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.0962 of 5 stars	3.4	3.0	0.0	4.8	0.0	2.5	0.6
AERI Aerie Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALGS Aligos Therapeutics	3.7748 of 5 stars	3.5	3.0	0.0	4.8	0.0	1.7	0.0
CLLS Cellectis	3.1593 of 5 stars	3.5	3.0	0.0	0.0	2.6	2.5	0.6
PASG Passage Bio	2.8264 of 5 stars	3.5	3.0	0.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	837.01% Upside
AERI Aerie Pharmaceuticals	0.00	N/A	N/A	N/A
ALGS Aligos Therapeutics	3.00	Buy	$70.00	737.32% Upside
CLLS Cellectis	3.00	Buy	$4.00	151.57% Upside
PASG Passage Bio	3.00	Buy	$7.50	1,770.79% Upside

Current Analyst Ratings Breakdown

Latest PASG, ALGS, ADVM, CLLS, and AERI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	53.06	N/A	N/A	$3.40 per share	0.75
AERI Aerie Pharmaceuticals	$194.13M	3.88	N/A	N/A	($3.32) per share	-4.59
ALGS Aligos Therapeutics	$3.94M	12.96	N/A	N/A	($7.50) per share	-1.11
CLLS Cellectis	$49.22M	1.80	N/A	N/A	$2.36 per share	0.67
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
AERI Aerie Pharmaceuticals	-$74.81M	-$0.77	N/A	N/A	N/A	-17.09%	N/A	-2.00%	N/A
ALGS Aligos Therapeutics	-$131.21M	-$17.51	N/A	N/A	N/A	-1,628.75%	14.67%	7.19%	8/5/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)

Latest PASG, ALGS, ADVM, CLLS, and AERI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	N/A	N/A	N/A	$0.43 million	N/A
8/5/2025	N/A	CLLS Cellectis	-$0.15	N/A	N/A	N/A	$10.07 million	N/A
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/6/2025	Q1 2025	ALGS Aligos Therapeutics	-$2.80	-$2.11	+$0.69	-$2.11	$0.33 million	$0.31 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
AERI Aerie Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
AERI Aerie Pharmaceuticals	N/A	2.27	1.92
ALGS Aligos Therapeutics	N/A	7.56	7.56
CLLS Cellectis	0.44	1.67	1.67
PASG Passage Bio	N/A	3.74	3.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
AERI Aerie Pharmaceuticals	95.94%
ALGS Aligos Therapeutics	60.43%
CLLS Cellectis	63.90%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
AERI Aerie Pharmaceuticals	4.44%
ALGS Aligos Therapeutics	4.80%
CLLS Cellectis	16.41%
PASG Passage Bio	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
AERI Aerie Pharmaceuticals	376	49.42 million	47.22 million	Optionable
ALGS Aligos Therapeutics	90	6.11 million	5.82 million	No Data
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
PASG Passage Bio	130	62.15 million	59.04 million	Optionable

PASG, ALGS, ADVM, CLLS, and AERI Headlines

Recent News About These Companies

Passage Bio Announces 1-for-20 Reverse Stock Split

July 10 at 7:00 AM | globenewswire.com

Passage Bio, Inc. (PASG) Income Statement - Yahoo Finance

July 1, 2025 | finance.yahoo.com

PASG Passage Bio, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 Shares

June 27, 2025 | insidertrades.com

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

June 23, 2025 | globenewswire.com

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025 | msn.com

Passage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestre

May 13, 2025 | zonebourse.comZ

PASSAGE BIO, INC. : Wedbush persiste à l'achat

May 13, 2025 | zonebourse.comZ

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

May 13, 2025 | globenewswire.com

Insider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of Stock

April 25, 2025 | insidertrades.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 Shares

April 18, 2025 | insidertrades.com

OrbiMed Advisors vend des actions de Passage Bio pour 49.704$

April 18, 2025 | fr.investing.com

L’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marché

April 8, 2025 | fr.investing.com

L’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$

March 31, 2025 | fr.investing.com

L'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$

March 14, 2025 | fr.investing.com

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

March 7, 2025 | zacks.com

PASSAGE BIO, INC. : Chardan Research reste à l'achat

March 5, 2025 | zonebourse.comZ

L’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$

March 5, 2025 | fr.investing.com

Passage Bio price target lowered to $6 from $7 at Chardan

March 5, 2025 | markets.businessinsider.com

Passage Bio publie ses résultats du quatrième trimestre et de l'année 2024.

March 4, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, ALGS, ADVM, CLLS, and AERI Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.54 -0.18 (-6.62%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 -0.04 (-1.77%)

As of 05:02 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Aligos Therapeutics NASDAQ:ALGS

$8.36 -0.43 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$8.38 +0.02 (+0.24%)

As of 06:19 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Cellectis NASDAQ:CLLS

$1.59 -0.06 (-3.64%)

Closing price 04:00 PM Eastern

Extended Trading

$1.55 -0.04 (-2.52%)

As of 05:37 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Passage Bio NASDAQ:PASG

$0.40 +0.00 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$0.37 -0.03 (-6.96%)

As of 06:41 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time